Matrix extracellular phosphoglycoprotein

WikiDoc Resources for Matrix extracellular phosphoglycoprotein
Articles
Most recent articles on Matrix extracellular phosphoglycoprotein Most cited articles on Matrix extracellular phosphoglycoprotein Review articles on Matrix extracellular phosphoglycoprotein Articles on Matrix extracellular phosphoglycoprotein in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Matrix extracellular phosphoglycoprotein Images of Matrix extracellular phosphoglycoprotein Photos of Matrix extracellular phosphoglycoprotein Podcasts & MP3s on Matrix extracellular phosphoglycoprotein Videos on Matrix extracellular phosphoglycoprotein
Evidence Based Medicine
Cochrane Collaboration on Matrix extracellular phosphoglycoprotein Bandolier on Matrix extracellular phosphoglycoprotein TRIP on Matrix extracellular phosphoglycoprotein
Clinical Trials
Ongoing Trials on Matrix extracellular phosphoglycoprotein at Clinical Trials.gov Trial results on Matrix extracellular phosphoglycoprotein Clinical Trials on Matrix extracellular phosphoglycoprotein at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Matrix extracellular phosphoglycoprotein NICE Guidance on Matrix extracellular phosphoglycoprotein NHS PRODIGY Guidance FDA on Matrix extracellular phosphoglycoprotein CDC on Matrix extracellular phosphoglycoprotein
Books
Books on Matrix extracellular phosphoglycoprotein
News
Matrix extracellular phosphoglycoprotein in the news Be alerted to news on Matrix extracellular phosphoglycoprotein News trends on Matrix extracellular phosphoglycoprotein
Commentary
Blogs on Matrix extracellular phosphoglycoprotein
Definitions
Definitions of Matrix extracellular phosphoglycoprotein
Patient Resources / Community
Patient resources on Matrix extracellular phosphoglycoprotein Discussion groups on Matrix extracellular phosphoglycoprotein Patient Handouts on Matrix extracellular phosphoglycoprotein Directions to Hospitals Treating Matrix extracellular phosphoglycoprotein Risk calculators and risk factors for Matrix extracellular phosphoglycoprotein
Healthcare Provider Resources
Symptoms of Matrix extracellular phosphoglycoprotein Causes & Risk Factors for Matrix extracellular phosphoglycoprotein Diagnostic studies for Matrix extracellular phosphoglycoprotein Treatment of Matrix extracellular phosphoglycoprotein
Continuing Medical Education (CME)
CME Programs on Matrix extracellular phosphoglycoprotein
International
Matrix extracellular phosphoglycoprotein en Espanol Matrix extracellular phosphoglycoprotein en Francais
Business
Matrix extracellular phosphoglycoprotein in the Marketplace Patents on Matrix extracellular phosphoglycoprotein
Experimental / Informatics
List of terms related to Matrix extracellular phosphoglycoprotein

Matrix, extracellular phosphoglycoprotein with ASARM motif (bone), also known as MEPE, is a human gene.

Phosphatonins have a role in phosphate homeostasis and the relationship between phosphate handling by the kidney and gastrointestinal tract. Matrix extracellular phosphoglycoprotein (MEPE), one of several candidate phosphatonins, promotes phosphaturia. Short-term infusion of MEPE inhibits phosphate absorption in the jejunum but not the duodenum. The phosphaturic action of MEPE may correlate with a significant reduction in renal sodium-phosphate co-transporter NaPi-IIa in the proximal convoluted tubules of the outer renal cortex. This short-term inhibitory effect of MEPE on renal and intestinal phosphate handling occurs without changes in the circulating levels of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D(3), or fibroblast growth factor 23 (FGF23). MEPE may be involved in phosphate homeostasis, acting in both the kidney and the gastrointestinal tract.

Further reading

• Quarles LD (2003). "FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization". Am. J. Physiol. Endocrinol. Metab. 285 (1): E1–9. doi:10.1152/ajpendo.00016.2003. PMID 12791601.
• Ogbureke KU, Fisher LW (2005). "Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)". Kidney Int. 68 (1): 155–66. doi:10.1111/j.1523-1755.2005.00389.x. PMID 15954904.
• Ogbureke KU, Fisher LW (2004). "Expression of SIBLINGs and their partner MMPs in salivary glands". J. Dent. Res. 83 (9): 664–70. doi:10.1177/154405910408300902. PMID 15329369.
• Jain A, Fedarko NS, Collins MT; et al. (2004). "Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density". J. Clin. Endocrinol. Metab. 89 (8): 4158–61. doi:10.1210/jc.2003-032031. PMID 15292364.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• Nampei A, Hashimoto J, Hayashida K; et al. (2005). "Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone". J. Bone Miner. Metab. 22 (3): 176–84. doi:10.1007/s00774-003-0468-9. PMID 15108058.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
• MacDougall M, Simmons D, Gu TT, Dong J (2003). "MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21". Connect. Tissue Res. 43 (2–3): 320–30. doi:10.1080/713713461. PMID 12489176.CS1 maint: Multiple names: authors list (link)
• Argiro L, Desbarats M, Glorieux FH, Ecarot B (2001). "Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone". Genomics. 74 (3): 342–51. doi:10.1006/geno.2001.6553. PMID 11414762.CS1 maint: Multiple names: authors list (link)
• Rowe PS, de Zoysa PA, Dong R; et al. (2000). "MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia". Genomics. 67 (1): 54–68. doi:10.1006/geno.2000.6235. PMID 10945470.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)